• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Graphite Bio Inc. (Amendment)

    3/25/24 8:42:49 PM ET
    $GRPH
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $GRPH alert in real time by email
    SC 13G/A 1 tm249756d1_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934
    (Amendment No. 3)*

     

    LENZ Therapeutics, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.00001 per share

    (Title of Class of Securities)

     

    52635N103

    (CUSIP Number)

     

    March 21, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)
    x Rule 13d-1(c)
    ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

     

    CUSIP No. 52635N103
     
      1. Names of Reporting Persons
    Samsara BioCapital, L.P.
     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) ¨
        (b) x (1)
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization
    Delaware

         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5. Sole Voting Power
    0
     
    6. Shared Voting Power
    1,208,473 shares (2)
     
    7. Sole Dispositive Power
    0
     
    8. Shared Dispositive Power
    1,208,473 shares (2)

         
      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    1,208,473 shares (2)
     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ¨
     
      11. Percent of Class Represented by Amount in Row (9)
    4.7% (3)
     
      12. Type of Reporting Person (See Instructions)
    PN

     

    (1)This Schedule 13G is filed by Samsara BioCapital, L.P. (“Samsara LP”), Samsara BioCapital GP, LLC (“Samsara GP”), 436, L.P. (“436 LP”), 436 GP, LLC (“436 LLC”) and Dr. Srinivas Akkaraju (“Akkaraju”) (and together with Samsara LP, Samsara GP, 436 LP and 436 LLC, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

    (2)These shares are held by Samsara LP. Samsara GP is the sole general partner of Samsara LP and may be deemed to have voting and investment power over the securities held by Samsara LP. Akkaraju is a managing member of Samsara GP and may be deemed to have voting and dispositive power over the shares held by Samsara LP.

    (3)This percentage is calculated based on 25,533,533 shares of Common Stock outstanding as of as of March 21, 2024 as reported in the Issuer’s Current Report on Form 8-K filed on March 22, 2024 with the Securities and Exchange Commission (the “SEC”).

     

     

     

     

    CUSIP No. 52635N103
     
      1. Names of Reporting Persons
    Samsara BioCapital GP, LLC
     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) ¨
        (b) x (1)
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization
    Delaware

         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5. Sole Voting Power
    0
     
    6. Shared Voting Power
    1,208,473 shares (2)
     
    7. Sole Dispositive Power
    0
     
    8. Shared Dispositive Power
    1,208,473 shares (2)

       
      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    1,208,473 shares (2)
       
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ¨
       
      11. Percent of Class Represented by Amount in Row (9)
    4.7% (3)
       
      12. Type of Reporting Person (See Instructions)
    OO

     

    (1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

    (2)These shares are held by Samsara LP. Samsara GP is the sole general partner of Samsara LP and may be deemed to have voting and investment power over the securities held by Samsara LP. Akkaraju is a managing member of Samsara GP and may be deemed to have voting and dispositive power over the shares held by Samsara LP.

    (3)This percentage is calculated based on 25,533,533 shares of Common Stock outstanding as of as of March 21, 2024 as reported in the Issuer’s Current Report on Form 8-K filed on March 22, 2024 with the SEC.

     

     

     

     

    CUSIP No. 52635N103
     
      1. Names of Reporting Persons
    436, L.P.
     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) ¨
        (b) x (1)
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization
    Delaware

         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5. Sole Voting Power
    0
     
    6. Shared Voting Power
    5,392 shares (2)
     
    7. Sole Dispositive Power
    0
     
    8. Shared Dispositive Power
    5,392 shares (2)

         
      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    5,392 shares (2)
     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ¨
     
      11. Percent of Class Represented by Amount in Row (9)
    0.0% (3)
     
      12. Type of Reporting Person (See Instructions)
    PN

     

    (1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

    (2)These shares are held by 436 LP. 436 LLC is the sole general partner of 436 LP and may be deemed to have voting and investment power over the securities held by 436 LP. Akkaraju is a managing member of 436 LLC and may be deemed to have voting and dispositive power over the shares held by 436 LP.

    (3)This percentage is calculated based on 25,533,533 shares of Common Stock outstanding as of as of March 21, 2024 as reported in the Issuer’s Current Report on Form 8-K filed on March 22, 2024 with the SEC.

     

     

     

     

    CUSIP No. 52635N103
     
      1. Names of Reporting Persons
    436 GP, LLC
     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) ¨
        (b) x (1)
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization
    Delaware

         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5. Sole Voting Power
    0
     
    6. Shared Voting Power
    5,392 shares (2)
     
    7. Sole Dispositive Power
    0
     
    8. Shared Dispositive Power
    5,392 shares (2)

         
      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    5,392 shares (2)
     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ¨
     
      11. Percent of Class Represented by Amount in Row (9)
    0.0% (3)
     
      12. Type of Reporting Person (See Instructions)
    OO

     

    (1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

    (2)These shares are held by 436 LP. 436 LLC is the sole general partner of 436 LP and may be deemed to have voting and investment power over the securities held by 436 LP. Akkaraju is a managing member of 436 LLC and may be deemed to have voting and dispositive power over the shares held by 436 LP.

    (3)This percentage is calculated based on 25,533,533 shares of Common Stock outstanding as of as of March 21, 2024 as reported in the Issuer’s Current Report on Form 8-K filed on March 22, 2024 with the SEC.

     

     

     

     

    CUSIP No. 52635N103
     
      1. Names of Reporting Persons
    Dr. Srinivas Akkaraju
     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) ¨
        (b) x (1)
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization
    United States of America

         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5. Sole Voting Power
    0
     
    6. Shared Voting Power
    1,213,865 shares (2)
     
    7. Sole Dispositive Power
    0
     
    8. Shared Dispositive Power
    1,213,865 shares (2)
     

      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    1,213,865 shares (2)
     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ¨
     
      11. Percent of Class Represented by Amount in Row (9)
    4.8% (3)
     
      12. Type of Reporting Person (See Instructions)
    IN

     

    (1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

    (2)Includes 1,208,473 shares of Common Stock held by Samsara LP and 5,392 shares of Common Stock held by 436 LP. Samsara GP is the sole general partner of Samsara LP and may be deemed to have voting and investment power over the securities held by Samsara LP. Akkaraju is a managing member of Samsara GP and may be deemed to have voting and dispositive power over the shares held by Samsara LP. 436 LLC is the sole general partner of 436 LP and may be deemed to have voting and investment power over the securities held by 436 LP. Akkaraju is a managing member of 436 LLC and may be deemed to have voting and dispositive power over the shares held by 436 LP.

    (3)This percentage is calculated based on 25,533,533 shares of Common Stock outstanding as of as of March 21, 2024 as reported in the Issuer’s Current Report on Form 8-K filed on March 22, 2024 with the SEC.

     

     

     

     

    Item 1.
      (a) Name of Issuer
    LENZ Therapeutics, Inc. (formerly Graphite Bio, Inc.)
      (b) Address of Issuer’s Principal Executive Offices
    445 Marine View Ave., Ste. #320
    Del Mar, CA 92014
     
    Item 2.
      (a)

    Name of Person Filing
    Samsara BioCapital, L.P. (“Samsara LP”)

    Samsara BioCapital GP, LLC (“Samsara GP”)

    436, L.P. (“436 LP”)

    436 GP, LLC (“436 LLC”)

    Srinivas Akkaraju (“Akkaraju”)

      (b)

    Address of Principal Business Office or, if none, Residence
    c/o Samsara BioCapital, LLC

    628 Middlefield Road

    Palo Alto, CA 94301

      (c) Citizenship

    Entities:Samsara LP - Delaware
    Samsara GP - Delaware
    436 L.P. - Delaware
    436 LLC - Delaware
           
    Individuals:Akkaraju - United States of America

      (d) Title of Class of Securities
    Common Stock, par value $0.00001 per share
      (e) CUSIP Number
    52635N103
     
    Item 3. If this statement is filed pursuant to §§240.03d-1(b) or 240.03d-2(b) or (c), check whether the person filing is a:
      Not applicable.

     

     

     

     

    Item 4. Ownership
    The beneficial ownership information set forth below is provided as of March 21, 2024:

     

    Reporting Persons 

    Shares Held

    Directly

      

    Sole

    Voting

    Power

      

    Shared

    Voting

    Power

      

    Sole

    Dispositive

    Power

      

    Shared

    Dispositive

    Power

      

    Beneficial

    Ownership

      

    Percentage

    of Class (5)

     
    Samsara LP (1) (2)   1,208,473       1,208,473        1,208,473    1,208,473    4.7%
                                      
    Samsara GP (1) (2)            1,208,473       1,208,473    1,208,473    4.7%
                                      
    436 LP (3) (4)   5,392        5,392        5,392    5,392    0.0%
                                      
    436 LLC (3) (4)            5,392        5,392    5,392    0.0%
                                      
    Akkaraju (1) (2) (3) (4)            1,213,865        1,213,865    1,213,865    4.8%

     

    (1)Includes 1,208,473 shares of Common Stock held by Samsara LP.
      
    (2)Samsara GP is the sole general partner of Samsara LP and may be deemed to have voting and investment power over the securities held by Samsara LP. Akkaraju is a managing member of Samsara GP and may be deemed to have voting and dispositive power over the shares held by Samsara LP.
      
    (3)Includes 5,392 shares of Common Stock held by 436 LP.
      
    (4)436 LLC is the sole general partner of 436 LP and may be deemed to have voting and investment power over the securities held by 436 LP. Akkaraju is a managing member of 436 LLC and may be deemed to have voting and dispositive power over the shares held by 436 LP.
      
    (5)This percentage is calculated based on 25,533,533 shares of Common Stock outstanding as of as of March 21, 2024 as reported in the Issuer’s Current Report on Form 8-K filed on March 22, 2024 with the SEC.

     
    Item 5. Ownership of Five Percent or Less of a Class
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following   x.
     
    Item 6. Ownership of More than Five Percent on Behalf of Another Person
    Not applicable.
     
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
    Not applicable.
     
    Item 8. Identification and Classification of Members of the Group
    Not applicable.
     
    Item 9. Notice of Dissolution of Group
    Not applicable.
     
    Item 10. Certification
    By signing below, each of the undersigned certifies that, to the best of their knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.04a-11.

     

     

     

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: March 25, 2024

     

    Samsara BioCapital, L.P.   Samsara BioCapital GP, LLC
         
    By: Samsara BioCapital GP, LLC    
    its General Partner    
         
    By: /s/ Srinivas Akkaraju   By: /s/ Srinivas Akkaraju
    Name: Srinivas Akkaraju     Name: Srinivas Akkaraju
    Title: Managing Member     Title: Managing Member
           
    436, L.P.   436 GP, LLC
           
    By: 436 GP, LLC    
    its General Partner    
           
    By: /s/ Srinivas Akkaraju   By: /s/ Srinivas Akkaraju
    Name: Srinivas Akkaraju     Name: Srinivas Akkaraju
    Title: Managing Member     Title: Managing Member
           
    /s/ Srinivas Akkaraju    
    Srinivas Akkaraju    

     

      ATTENTION  
    Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

     

     

     

    Get the next $GRPH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GRPH

    DatePrice TargetRatingAnalyst
    2/23/2023$3.00 → $2.00Neutral → Underperform
    BofA Securities
    2/23/2023$3.00Overweight → Neutral
    Cantor Fitzgerald
    2/23/2023Outperform → Market Perform
    Cowen
    1/25/2023Buy → Neutral
    BTIG Research
    1/18/2023$7.00 → $3.00Buy → Neutral
    BofA Securities
    1/6/2023$11.00 → $2.00Outperform → Mkt Perform
    SVB Leerink
    1/6/2023$14.00 → $7.00Outperform → Market Perform
    BMO Capital Markets
    9/15/2022$12.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $GRPH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Graphite Bio Declares Special Dividend In Connection with Proposed Merger with Lenz Therapeutics

      Special dividend estimated to be $1.03 per share Payment of special dividend conditioned upon closing of merger Graphite Bio, Inc. (NASDAQ:GRPH) ("Graphite" or the "Company") today announced that its Board of Directors has declared a special dividend in connection with the previously announced merger (the "Merger") with Lenz Therapeutics, Inc. ("LENZ") pursuant to the Agreement and Plan of Merger, dated November 14, 2023 (the "Merger Agreement"). The special dividend, which the Company estimates will be $1.03 per share of Graphite's common stock, will be payable in cash to the stockholders of record as of March 18, 2024. The exact amount of the special dividend will be calculated afte

      3/8/24 5:00:00 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • LENZ Therapeutics and Graphite Bio Announce Merger Agreement

      - Merger to create NASDAQ-listed, late clinical-stage biopharmaceutical company focused on advancing LENZ Therapeutics' lead assets for the treatment of presbyopia - Combined company expected to have approximately $225 million of cash or cash equivalents at close, including $53.5 million from a concurrent PIPE financing - Companies to host joint webcast today, November 15, 2023 at 8:00 a.m. ET LENZ Therapeutics, a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision, and Graphite Bio, Inc. (NASDAQ:GRPH) today announced that they have entered into a definitive merger agreement to combine the companies in an all-stock tran

      11/15/23 7:00:00 AM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • Healthpeak Properties Reports Third Quarter 2023 Results and Declares Quarterly Cash Dividend on Common Stock

      Healthpeak Properties, Inc. (NYSE:PEAK), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, today announced results for the third quarter ended September 30, 2023. THIRD QUARTER 2023 FINANCIAL PERFORMANCE AND RECENT HIGHLIGHTS – Net income of $0.12 per share, Nareit FFO of $0.46 per share, FFO as Adjusted of $0.45 per share, AFFO of $0.40 per share, and blended Total Same-Store Portfolio Cash (Adjusted) NOI growth of 6.0% – Third quarter new and renewal lease executions totaled 2.3 million square feet: • Outpatient Medical new and renewal lease executions totaled 2.1 million square feet, an all-time quarterly high, including a 1.3 millio

      10/30/23 7:00:00 AM ET
      $GRPH
      $PEAK
      Medicinal Chemicals and Botanical Products
      Health Care
      Real Estate Investment Trusts
      Real Estate

    $GRPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Graphite Bio downgraded by BofA Securities with a new price target

      BofA Securities downgraded Graphite Bio from Neutral to Underperform and set a new price target of $2.00 from $3.00 previously

      2/23/23 8:58:13 AM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • Graphite Bio downgraded by Cantor Fitzgerald with a new price target

      Cantor Fitzgerald downgraded Graphite Bio from Overweight to Neutral and set a new price target of $3.00

      2/23/23 8:56:04 AM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • Graphite Bio downgraded by Cowen

      Cowen downgraded Graphite Bio from Outperform to Market Perform

      2/23/23 6:14:16 AM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care

    $GRPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Mccollum James W bought $501,093 worth of shares (31,332 units at $15.99) (SEC Form 4)

      4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

      5/14/24 5:29:43 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • New insider Alpha Wave Ventures Gp, Ltd claimed ownership of 3,612,211 shares (SEC Form 3)

      3 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

      3/28/24 4:31:03 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • Ra Capital Management, L.P. was granted 3,245,785 shares, bought $14,023,561 worth of shares (933,038 units at $15.03) and bought $976,514 worth of Common Stockj (64,971 units at $15.03) (SEC Form 4)

      4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

      3/25/24 8:48:33 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care

    $GRPH
    Financials

    Live finance-specific insights

    See more
    • Graphite Bio Declares Special Dividend In Connection with Proposed Merger with Lenz Therapeutics

      Special dividend estimated to be $1.03 per share Payment of special dividend conditioned upon closing of merger Graphite Bio, Inc. (NASDAQ:GRPH) ("Graphite" or the "Company") today announced that its Board of Directors has declared a special dividend in connection with the previously announced merger (the "Merger") with Lenz Therapeutics, Inc. ("LENZ") pursuant to the Agreement and Plan of Merger, dated November 14, 2023 (the "Merger Agreement"). The special dividend, which the Company estimates will be $1.03 per share of Graphite's common stock, will be payable in cash to the stockholders of record as of March 18, 2024. The exact amount of the special dividend will be calculated afte

      3/8/24 5:00:00 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • LENZ Therapeutics and Graphite Bio Announce Merger Agreement

      - Merger to create NASDAQ-listed, late clinical-stage biopharmaceutical company focused on advancing LENZ Therapeutics' lead assets for the treatment of presbyopia - Combined company expected to have approximately $225 million of cash or cash equivalents at close, including $53.5 million from a concurrent PIPE financing - Companies to host joint webcast today, November 15, 2023 at 8:00 a.m. ET LENZ Therapeutics, a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision, and Graphite Bio, Inc. (NASDAQ:GRPH) today announced that they have entered into a definitive merger agreement to combine the companies in an all-stock tran

      11/15/23 7:00:00 AM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • Healthpeak Properties Reports Third Quarter 2023 Results and Declares Quarterly Cash Dividend on Common Stock

      Healthpeak Properties, Inc. (NYSE:PEAK), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, today announced results for the third quarter ended September 30, 2023. THIRD QUARTER 2023 FINANCIAL PERFORMANCE AND RECENT HIGHLIGHTS – Net income of $0.12 per share, Nareit FFO of $0.46 per share, FFO as Adjusted of $0.45 per share, AFFO of $0.40 per share, and blended Total Same-Store Portfolio Cash (Adjusted) NOI growth of 6.0% – Third quarter new and renewal lease executions totaled 2.3 million square feet: • Outpatient Medical new and renewal lease executions totaled 2.1 million square feet, an all-time quarterly high, including a 1.3 millio

      10/30/23 7:00:00 AM ET
      $GRPH
      $PEAK
      Medicinal Chemicals and Botanical Products
      Health Care
      Real Estate Investment Trusts
      Real Estate

    $GRPH
    SEC Filings

    See more
    • SEC Form 424B3 filed by Graphite Bio Inc.

      424B3 - LENZ Therapeutics, Inc. (0001815776) (Filer)

      5/9/24 4:18:06 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 10-Q filed by Graphite Bio Inc.

      10-Q - LENZ Therapeutics, Inc. (0001815776) (Filer)

      5/8/24 5:11:18 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • Graphite Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - LENZ Therapeutics, Inc. (0001815776) (Filer)

      5/8/24 4:05:56 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care

    $GRPH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Mccollum James W bought $501,093 worth of shares (31,332 units at $15.99) (SEC Form 4)

      4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

      5/14/24 5:29:43 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • Ra Capital Management, L.P. was granted 3,245,785 shares, bought $14,023,561 worth of shares (933,038 units at $15.03) and bought $976,514 worth of Common Stockj (64,971 units at $15.03) (SEC Form 4)

      4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

      3/25/24 8:48:33 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care

    $GRPH
    Leadership Updates

    Live Leadership Updates

    See more
    • Graphite Bio Appoints Alethia Young as Chief Financial Officer

      Graphite Bio, Inc. (NASDAQ:GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced the appointment of Alethia Young as chief financial officer. Ms. Young joins Graphite Bio from Cantor Fitzgerald, where she served as senior biotech analyst and head of research, managing the equity research department covering small-cap, mid-cap and large-cap biotechnology companies. In this newly created position, Ms. Young will oversee the company's finance, investor relations and corporate communications functions, and will play a key role in overall corporate strategy. "On behalf of the e

      3/2/22 8:00:00 AM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care

    $GRPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Graphite Bio Inc. (Amendment)

      SC 13G/A - LENZ Therapeutics, Inc. (0001815776) (Subject)

      4/8/24 2:46:09 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Graphite Bio Inc.

      SC 13G - LENZ Therapeutics, Inc. (0001815776) (Subject)

      3/28/24 4:30:24 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13D filed by Graphite Bio Inc.

      SC 13D - LENZ Therapeutics, Inc. (0001815776) (Subject)

      3/28/24 4:16:06 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care